We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
  • SKIP TO CONTENT
  • SKIP NAVIGATION
  • Drug Products
    • Books
    • FDAnews Books Library
    • Events
    • Form 483s Database
    • Subscription Newsletters
    • Free Newsletters
    • Webinar Training Pass
    • eCFR and Guidances
  • Device Products
    • Books
    • FDAnews Books Library
    • Events
    • Form 483s Database
    • Subscription Newsletters
    • Free Newsletters
    • Webinar Training Pass
    • eCFR and Guidances
  • Clinical Products
  • Advertising
  • White Papers
  • Contact Us
  • About Us
  • COVID-19
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » ATTORNEY: FDA USING PLAN B LETTER TO HEAD OFF LITIGATION

ATTORNEY: FDA USING PLAN B LETTER TO HEAD OFF LITIGATION

June 14, 2006

The FDA's recent letter rejecting a citizen petition for OTC sale of the controversial contraceptive Plan B is meant to be a legal broadside, heading off Plan B lawsuits by making clear how solid the agency's legal footing is, a legal expert said.

The FDA used a June 9 letter rejecting the Center for Reproductive Rights' (CRR) petition asking the agency to approve Plan B for OTC use to argue that CRR lacks the standing to push the issue in court. CRR, which has filed a lawsuit against the FDA to force it to approve Plan B, does not have the legal authority to act on the company's behalf because there it has no "commercial, financial, associational, fiduciary or confidential relationship with Barr," the letter said.

The agency is "completely correct" in its legal arguments, Peter Barton Hutt, senior counsel at Covington and Burling and former FDA general counsel told DID. The law is clear that a party that lacks any of those relationships with Barr cannot represent its interests in court, Hutt added. "CRR hasn't got a leg to stand on, in my judgment."

The agency's decision to lay out its reasoning is driven by its desire to undermine CRR's ongoing suit against the FDA and discourage future Plan B lawsuits, he said. The agency is "in effect, filing its brief in court ahead of time, trying to head off further litigation."

However, CRR rejects this argument. The letter will have "no impact at all," CRR attorney Priscilla Smith told FDAnews. The court has already established that CRR has standing to challenge the FDA's review when it rejected an earlier government motion to dismiss, she said. The group is not acting on Barr's behalf, but instead is representing doctors and, by extension, their patients who would use Plan B, she added.

By issuing the letter, the agency diverged from its traditional practice of withholding a decision on a citizen petition when a similar supplemental new drug application is pending. A response is warranted in this case, the agency letter said, because of "the significant public interest in the issues raised by your petition."

The agency faces increasing pressure from lawmakers such as Sen. Edward Kennedy (D-Mass.), the ranking member of the Senate Health, Education, Labor and Pensions Committee, to make a decision on the Barr application. Sens. Patty Murray (D-Wash.) and Hillary Rodham Clinton (D-N.Y.) had earlier held up Andrew von Eschenbach, President Bush's nominee to be the FDA commissioner, because of the Plan B controversy. (http://www.fdanews.com/did/5_116/)

KEYWORDS FDAnews Drug Daily Bulletin

Upcoming Events

  • 19Jan

    Pharmaceutical Quality Risk Management: Navigating the Intersection Between Regulatory Requirements & Risk Management

  • 21Jan

    Virtual MDSAP Audits in the Era of COVID-19: What to Know and Do to Pass Virtual Audits

  • 26Jan

    Reducing Complexity in Starting Clinical Trials – More Patients, Faster Startup

  • 27Jan

    Medical Device Clinical Trials in China: Latest Regulatory Developments

  • 27Jan

    FDA’s Response to COVID-19: Fundamentals of Obtaining Emergency Use Authorizations

  • 09Feb

    Maintaining Your Risk-Based Cleaning and Disinfectant Programs: Best Practices During COVID-19

Featured Products

  • Biological Risk Evaluation and Management for Medical Devices

  • GMP Inspection Preparation Checklist: A Tool for Internal Auditing

Featured Stories

  • Regeneron logo

    U.S. Government Orders More Supplies of Regeneron’s COVID-19 Antibody Cocktail

  • Siemens Healthineers logo

    Siemens Healthineers COVID Test Gets Additional Sampling Method Clearance

  • COVID-19  Clinical Trial

    Synairgen Initiates Dosing in Late-Stage Trial of Inhaled COVID-19 Therapy

  • Verona Pharma logo

    Verona Pharma Ends Enrollment in Inhaler-Administered COVID-19 Drug Pilot

The Revised ICH E8: A Guide to New Clinical Trial Requirements

Learn More
  • Drug Products
    • Quality
    • Regulatory Affairs
    • GMPs
    • Inspections and Audits
    • Postmarket Safety
    • Submissions and Approvals
    • Research and Development
    • Commercial Operations
  • Device Products
    • Quality
    • Regulatory Affairs
    • QSR
    • Inspections and Audits
    • Postmarket Safety
    • Submissions and Approvals
    • Research and Development
    • Commercial Operations
  • Clinical Products
    • Trial Design
    • Data Integrity
    • GCP
    • Inspections and Audits
    • Transparency
  • Privacy Policy
  • Do Not Sell My Personal Information
Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 703.538.7600 – Fax 703.538.7676 – Toll free 888.838.5578

Copyright © 2021. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing